Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Green Growth Brands Inc. (GGBXF)
Columbus, OH, US
Green Growth Brands Inc., operating with its subsidiaries across the United States, manages the full spectrum of cannabis and cannabidiol (CBD)-infused consumer products, from growing and processing to production, distribution, and retail. The company supplies both medical and recreational marijuana products to various dispensaries. Additionally, it offers a diverse selection of CBD-infused personal care and beauty items, including therapeutic, face, body, bath, and sleep products, which are sold through its own retail locations, online stores, and wholesale distribution networks. Its product offerings are available under brand names like CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and Meri + Jayne. Founded in 1968, the company operated as Xanthic Biopharma Inc. until it adopted the name Green Growth Brands Inc. in January 2019. The company's main office is situated in Columbus, Ohio.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +900.00% | +900.00% | +0.00% | +0.00% | -99.86% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-519.2%
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-439.2%
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-371.5%
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-49.1%
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+367.6%
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.51×
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ed Kistner | Chief Administrative Officer | — | male |
| Jann Parish | Chief Marketing Officer | — | female |
| Julia Fulton | Investor & Public Relations Manager | — | female |
| Kellie Wurtzman | Chief Stores Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GGBXF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
